Biology of Inflammatory Products: Cytokines
Expression of Th1 and Th2 Immunoregulatory Cytokines by Human EosinophilsWoerly G. · Roger N. · Loiseau S. · Capron M.
INSERM U167, Institut Pasteur, and University of Lille II, Lille, France
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Besides cytotoxic mediators, human eosinophils can produce proinflammatory and anti–inflammatory cytokines, as well as growth factors and chemokines. The demonstration that eosinophils from patients could produce IL–5, IL–4 and IL–2 suggested their participation in the regulation of immune response. In the present work, we have examined the presence of Th1 (IFN–γ, IL–2) and Th2 (IL–4, IL–5, IL–10 and IL–13) cytokines in eosinophils from patients or donors by intracellular flow cytometry, and by immunocytochemistry. Whereas almost 100% eosinophils expressed intracellular IFN–γ, IL–2 and IL–10, the expression of IL–4, IL–5 and IL–13 is more variable and increased in patients versus donors. The differential release by eosinophils of Th2 versus Th1 cytokines is suggested both by the decrease of the intracellular content after culture, restricted to IL–4, IL–5 and IL–13, associated with an accumulation of IL–4 and IL–5 in the presence of Brefeldin. These results indicate that, through the preferential release of Th2 cytokines, human eosinophils can participate in the polarization of the immune response.
- Desreumaux P, Capron M: Eosinophils in allergic reactions. Curr Opin Immunol 1996;8: 790–795.
Dubucquoi S, Capron M: L’éosinophile, une cellule à deux visages dans la réponse inflammatoire; dans L’inflammation. London, Libbey, 1998, pp 55–68.
- Desreumaux P, Janin A, Colombel JF, Prin L, Plumas J, Emilie D, Torpier G, Capron A, Capron M: Interleukin–5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med 1992;175:293–296.
- Dubucquoi S, Desreumaux P, Janin A, Klein O, Goldman M, Tavernier J, Capron A, Capron M: Interleukin 5 synthesis by eosinophils: Association with granules and immunoglobulin–dependent secretion. J Exp Med 1994;179: 703–708.
- Broide DH, Paine MM, Firestein GS: Eosinophils express interleukin–5 and granulocyte macrophage–colony–stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992;90:1414–1424.
- Tanaka YE, Delaporte E, Dubucquoi S, Soussi Gounni A, Porchet E, Capron A, Capron M: IL–5 messenger RNA and immunoreactive protein expression by activated eosinophils in lesional atopic dermatitis skin. J Invest Dermatol 1994;103:589–592.
- Tomassini M, Tsicopoulos A, Tai PC, Gruart V, Tonnel AB, Prin L, Capron A, Capron M: Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin–dependent activation. J Allergy Clin Immunol 1991;88:365– 375.
- Nonaka M, Nonaka R, Woolley K, Adelroth E, Miura K, Okhawara Y, Glibetic M, Nakano K, O’Byrne P, Dolovich J, Jordana M: Distinct immunohistochemical localization of IL–4 in human inflamed airway tissues. Il–4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. J Immunol 1995; 155:3234–3244.
- Moqbel R, Ying S, Barkans J, Newman TM, Kimmitt P, Wakelin M, Taborda–Barata L, Meng Q, Corrigan CJ, Durham SR, Kay AB: Identification of messenger RNA for IL–4 in human eosinophils with granule localization and release of the translated product. J Immunol 1995;155:4939–4947.
- Swain SL, Weinberg AD, English M, Huston G: IL–4 directs the development of Th2–like helper effectors. J Immunol 1990;145:3796– 3806.
- Levi–Schaffer F, Barkans J, Newman TM, Ying S, Wakelin M, Hohenstein R, Barak V, Lacy P, Kay AB, Moqbel R: Identification of interleukin–2 in human peripheral blood eosinophils. Immunology 1996;87:155–161.
- Lamkhioued B, Soussi Gounni A, Aldebert D, Delaporte E, Prin L, Capron A, Capron, M: Synthesis of type 1 (IFN–γ) and type 2 (IL–4, IL–5, and IL–10) cytokines by human eosinophils. Ann NY Acad Sci 1996;796:203–208.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.